How to appeal an Aetna treatment-resistant depression — rtms, spravato, ect denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for treatment-resistant depression — rtms, spravato, ect

Cited policy: Aetna Clinical Policy Bulletin: Esketamine (Spravato)

TRD diagnosis: MDD with failure of >=2 adequate antidepressant trials at therapeutic dose >=6 wk in current episode (per FDA label). OR MDD with acute suicidal ideation/behavior (per Aug 2020 indication). Administered ONLY at REMS-certified site with >=2 hr post-dose monitoring (BP, sedation, dissociation). Reauth at induction completion (4 wk) with MADRS response; maintenance phase per SUSTAIN-1.

How Aetna denies treatment-resistant depression — rtms, spravato, ect — and how to counter it

Where Aetna pushes back: 1) Try ECT first; 2) Generic IV ketamine instead; 3) REMS site requirement reduces 'medical necessity'.

Counter-arguments that hold up: Spravato FDA-approved Mar 5, 2019 for TRD STANDALONE (with oral AD), Aug 3, 2020 for MDD with acute suicidal ideation. APA TRD 2022 + Voineskos JCP 2022 list ECT and esketamine as PARALLEL options — NOT step-therapy. TRANSFORM-2 Popova AJP 2019 — Spravato + AD vs AD-alone, primary endpoint met. SUSTAIN-1 Daly JAMA Psychiatry 2019 — relapse-prevention. ASPIRE-I/II — acute suicidal ideation. IV ketamine is OFF-LABEL; Spravato is FDA-approved with REMS — coverage required at REMS-certified site.

What Aetna typically denies for treatment-resistant depression — rtms, spravato, ect

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For treatment-resistant depression — rtms, spravato, ect, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the treatment-resistant depression — rtms, spravato, ect treatments most often flagged for prior auth, step therapy, or medical necessity review:

• NeuroStar rTMS (10 Hz)
• Brainsway Deep TMS
• Magstim Horizon rTMS
• MagVenture rTMS
• iTBS (theta-burst)
• SAINT / SNT accelerated iTBS

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.